COMMUNIQUÉS West-GlobeNewswire
      -   
  
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
03/10/2025 -   
  
Merit Medical Systems to Announce Third Quarter 2025 Results on October 30, 2025
03/10/2025 -   
  
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
03/10/2025 -   
  
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
03/10/2025 -   
  
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
03/10/2025 -   
  
Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting
03/10/2025 -   
  
Anathapindika Is Bringing Holistic Health to the US Through a Trio of Unconventional Nutraceutical Formulas
03/10/2025 -   
  
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
03/10/2025 -   
  
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
03/10/2025 -   
  
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
03/10/2025 -   
  
Anathapindika Health’s Detoxifying Supplements Are Headed to Retailers in the US
03/10/2025 -   
  
Enara Bio to Reveal DARKFOX, a Novel Cancer-Specific Dark Antigen with Broad-Ranging Therapeutic Potential, in Oral Presentation at SITC 2025
03/10/2025 -   
  
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off
03/10/2025 -   
  
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025 -   
  
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
03/10/2025 -   
  
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025 -   
  
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
03/10/2025 -   
  
Cartesian Therapeutics Announces New Employment Inducement Grant
03/10/2025 -   
  
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025 
Pages